ArticleFrontiers in medicine2025
Burden and risk factors for gallbladder and biliary tract diseases in China from 1990 to 2021 and burden predictions of risk factors for the next 15 years.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gallbladder and biliary tract diseases (GBDT) is a common digestive disorder; however, comprehensive epidemiological data from China are still limited. Methods: This study utilized the Global Burden of Disease Study 2021 database to examine the burden of GBDT from 1990 to 2021. The key metrics analyzed included age-standardized incidence rate (ASIR), prevalence rate (ASPR), rate of mortality (ASMR), and age-standardized disability-adjusted life years rate (ASDR). Furthermore, the study analyzed trends and future projections concerning GBDT linked to high body mass index (HBMI). Joinpoint regression analyses were performed to evaluate trends in disease burden from 1990 to 2021. Furthermore, the study analyzed trends in mortality and DALYs attributable to GBDT linked to high HBMI and made projections for HBMI-related GBDT mortality and disability-adjusted life years (DALYs) over the next 15 years. Results: From 1990 to 2021, the ASPR and ASIR of GBDT in China showed fluctuating trends, and the ASPR and ASIR of GBDT in globally also fluctuated similarly, but with a smaller amplitude, and the overall trend showed a decreasing trend. The ASMR showed a lower level with a stable trend, and the ASDR also showed a lower level but slowly decreased annually. The incidence, prevalence, mortality and DALYs of GBDT were correlated with old age and female. The burden of disease attributable to GBDT due to HBMI was concentrated in the very old. The BAPC model predicts an increase in the DALYs and a decrease in mortality, deaths, and DALYs rate for GBDT attributable to HBMI over the next 15 years. Conclusion: GBDT remains a major global public health problem, and the development trend of GBDT in China has far-reaching global implications. In China, the number of incident cases of GBDT and ASIR increased between 1990 and 2021, and GBDT, due to HBMI, poses a greater disease burden in China, both in the past and in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.